

**REVIEW**

# Systematic review of the association between short chain fatty acids and allergic diseases

Mari Sasaki<sup>1,2</sup>  | Noor H. A. Suaini<sup>3</sup>  | Jamie Afghani<sup>4,5,6</sup> | Kristina N. Heye<sup>7</sup> | Liam O'Mahony<sup>8,9,10</sup>  | Carina Venter<sup>11</sup>  | Roger Lauener<sup>7,12</sup> | Remo Frei<sup>2,12,13</sup> | Caroline Roduit<sup>1,2,7,12</sup> 

<sup>1</sup>University Children's Hospital Zürich, Zürich, Switzerland

<sup>2</sup>Division of Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, University of Bern, Bern, Switzerland

<sup>3</sup>Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A\*STAR), Singapore, Singapore

<sup>4</sup>Environmental Medicine Faculty of Medicine, University of Augsburg, Augsburg, Germany

<sup>5</sup>ZIEL-Institute for Food and Health, Technical University of Munich, Freising, Germany

<sup>6</sup>Institute of Environmental Medicine, Environmental Health Centre, Helmholtz Munich - German Research Centre for Environmental Health (GmbH), Neuherberg, Germany

<sup>7</sup>Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland

<sup>8</sup>Department of Medicine, University College Cork, National University of Ireland, Cork, Ireland

<sup>9</sup>APC Microbiome Ireland, University College Cork, National University of Ireland, Cork, Ireland

<sup>10</sup>School of Microbiology, University College Cork, National University of Ireland, Cork, Ireland

<sup>11</sup>Pediatric Allergy and Immunology, University of Colorado/Childrens Hospital Colorado, Aurora, Colorado, USA

<sup>12</sup>Christine Kühne Center for Allergy Research and Education (CK-CARE), Davos, Switzerland

<sup>13</sup>Department of Biomedical Research, University of Bern, Bern, Switzerland

**Correspondence**

Mari Sasaki, Division of Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, University of Bern, Bern, Switzerland, Freiburgstrasse 15, 3010 Bern, Switzerland.  
Email: [mari.sasaki.md@gmail.com](mailto:mari.sasaki.md@gmail.com)

**Abstract**

We performed a systematic review to investigate the current evidence on the association between allergic diseases and short chain fatty acids (SCFAs), which are microbially produced and suggested as one mechanism on how gut microbiome affects the risk of allergic diseases. Medline, Embase and Web of Science were searched from data inception until September 2022. We identified 37 papers, of which 17 investigated prenatal or early childhood SCFAs and the development of allergic diseases in childhood, and 20 assessed SCFAs in patients with pre-existing allergic diseases. Study design, study populations, outcome definition, analysis method and reporting of the results varied between papers. Overall, there was some evidence showing that the three main SCFAs (acetate, propionate and butyrate) in the first few years of life had a protective effect against allergic diseases, especially for atopic dermatitis, wheeze or asthma and IgE-mediated food allergy in childhood. The association between each SCFA and allergic disease appeared to be different by disease and the

**Abbreviations:** AD, atopic dermatitis; BCFAs, branched short chain fatty acids; NOS, Newcastle-Ottawa Scale; SCFAs, short chain fatty acids.

Remo Frei and Caroline Roduit share last authorship.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2024 The Authors. *Allergy* published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

age of assessment. Further research that can determine the potentially timing specific effect of each SCFA will be useful to investigate how SCFAs can be used in treatment or in prevention against allergic diseases.

#### KEYWORDS

allergic diseases, butyrate, gut microbiome, propionate, short chain fatty acids

## 1 | INTRODUCTION

The imbalance in the interaction between the gut microbiome and the immune system has been suggested to play a role in the development of many immune-mediated diseases, including allergic diseases.<sup>1,2</sup> Alterations in the composition of gut microbiota have been widely reported in both children and adults with allergic diseases.<sup>3-7</sup> However, the mechanism of how this affects the risk of allergic diseases remains unclear. Microbiota can directly affect the immune system by interaction with microbe-associated molecular patterns (e.g., lipopolysaccharide) or indirectly by microbially produced metabolites, namely short chain fatty acids (SCFAs).<sup>1,8,9</sup>

SCFAs are volatile fatty acids produced by the gut microbiota through fermentation of food components and refers to those with up to five to six carbons in straight or branched-chain formation.<sup>10</sup> Acetate (C2), propionate (C3) and butyrate (C4) represent 90–95% of the total SCFAs in the colon and are mostly final metabolic products of carbohydrate fermentation.<sup>11</sup> The gut microbiota also produce low levels of valerate (C5), caproate (C6) and branched short chain fatty acids (BCFAs), mainly iso-valeric acid and iso-butyric acid, which are produced by the fermentation of amino acids.<sup>10</sup> It is well known that SCFAs, especially butyrate, are important substrates for maintaining the colonic epithelium.<sup>12</sup> SCFAs have anti-inflammatory properties and influence the immune cells through various pathways via G-protein-coupled receptors and histone deacetylase inhibition.<sup>13,14</sup> Their effects include inhibiting the production of pro-inflammatory cytokines by innate immune cells, promoting B-cell antibody production and accelerating differentiation of FOXP3+ regulatory T cells (Tregs).<sup>8,9</sup> The promotion of Tregs is mediated through several mechanisms, such as butyrate and propionate inducing the differentiation from naïve CD4+ T cells and butyrate enhancing Treg generation by its effect on macrophages and dendritic cells, also inducing IL-10 producing T cells.<sup>15-17</sup> Direct delivery of SCFAs to the gut by oral administration or an enema has undergone human trials for the treatment of inflammatory bowel disease or colitis.<sup>18</sup> Additionally, although only a minor proportion of microbially produced SCFAs (especially for butyrate) reach systemic circulation and other tissues, the immunomodulatory functions of SCFAs have also been shown outside the gut, such as in the lung, skin and brain, within animal models.<sup>19-21</sup> There is increasing interest in the role of SCFAs as one of the mechanisms for how gut microbiota can affect the risk of allergic disease and as a potential method of intervention.

Here, we conducted a systematic review of studies that investigated the association between SCFAs and (i) the development of allergic diseases in childhood and (ii) pre-existing allergic diseases, to have a comprehensive understanding of the current epidemiological evidence for the protective role of SCFAs against allergic diseases.

## 2 | METHODS

This systematic review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance.<sup>22</sup>

The protocol of this systematic review was registered in PROSPERO (CRD42022324883) in May 2022.

### 2.1 | Eligibility criteria

We included observational studies and intervention studies that reported the association between the level of SCFAs in any human samples and allergic diseases in children and/or adults.

We included studies that identified or targeted one or more of the SCFAs- acetate, propionate, butyrate, valerate, caproate, iso-valeric and iso-butyric acid according to the level 1 and 2 annotation standards set forth.<sup>23,24</sup> Studies that (i) assessed SCFAs and future development of allergic diseases and (ii) assessed SCFAs in patients with pre-existing allergic diseases were included but reported separately. For the outcome of allergic diseases, studies on atopic dermatitis (AD), wheeze/asthma, allergic rhinitis, non-IgE-mediated and IgE-mediated food allergy and atopic sensitisation were included without limitation to their definitions (e.g., self-reported or physician diagnosis).

### 2.2 | Exclusion criteria

Animal studies, studies using untargeted metabolomics methods only, studies reported in a language other than English or conference abstracts were excluded. Intervention studies which compared short chain fatty acid (SCFA) levels only between the control and intervention group (and not between those with and without allergic diseases), studies that compared SCFAs by the response to a treatment or in which there was no healthy control group, were also excluded from this review.

## 2.3 | Search method

We searched Medline, Embase and Web of Science from database inception to September 2022. Search terms included, “allergy”, “allergic disease”, “atopic dermatitis”, “eczema”, “asthma”, “wheeze”, “allergic rhinitis”, “hayfever”, “SCFA”, “short chain fatty acid”, “acetate”, “acetic acid”, “propionate”, “propionic acid”, “butyrate”, “butyric acid”, “isobutyrate”, “isobutyric acid”, “caproate”, “hexanoic acid”, “metabolomics” and “lipidomics”. The full search terms are provided in supplementary material. The reference lists of eligible studies were also manually searched to identify additional literature. Two independent reviewers assessed the eligibility by screening the title and abstract, followed by the full text.

## 2.4 | Data extraction and risk of bias assessment

One reviewer (MS) completed data extractions, and data were confirmed with another reviewer (NS). Disagreements were resolved by consensus between the two reviewers. The risk of bias assessment was carried out using the Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies with some adjustments to the criteria.<sup>25</sup> A study can be awarded a maximum of one star for each numbered item within the selection and exposure categories and maximum of two stars can be given for comparability. We classified studies having 0–33% of the highest possible total number of stars as high risk, 34%–67% as medium risk and 68%–100% as low risk.

## 2.5 | Data synthesis

Results from the studies were summarised separately for (i) studies that investigated the association between SCFAs and future development of allergic diseases and (ii) those that reported the association between SCFAs and pre-existing allergic diseases. Papers compared SCFAs between cases and controls either by their level/concentration using the observed value, relative abundance (proportion among the total SCFA) or proportion of individuals with high levels using a certain cut-off value (e.g., median, 75 or 95 percentile) or a combination of these, and the observed levels of SCFAs were not always reported. Thus, meta-analysis was not carried out and results were summarised based on direction of effect—disease had an association with the SCFAs in the negative direction (decreased level or concentration, relative abundance or proportion of individuals with high value in cases compared with controls), an association in the positive direction (increased level or concentration, relative abundance or proportion of individuals with high value in cases compared with controls) or no association. Due to differences in how studies interpret significant *p*-values, for the purposes of this review, *p*-value <.05 was considered as a significant association.

## 3 | RESULTS

A total of 6411 papers were identified, of which 241 full texts were assessed, and 36 papers met the eligibility criteria. One paper was identified by searching the references, and so a total of 37 papers were included in this review (Figure 1). Among the papers included, 17 papers reported the association between SCFAs measured prior to the allergy outcome, while 20 papers reported on the association between SCFAs and pre-existing allergic diseases.

### 3.1 | SCFAs and allergy development

#### 3.1.1 | Study characteristics

A total of 17 papers used data from 13 studies, comprising 9 prospective cohort studies,<sup>26–42</sup> three interventional studies,<sup>32,34,42</sup> and one hospital-based case control study design with follow-up.<sup>40</sup> Sample size in terms of the number of individuals who had SCFAs compared in each paper was less than 50 in three,<sup>27,30,32</sup> between 50 and 100 in seven,<sup>26,28,31,35,37–39</sup> between 100 and 200 in four,<sup>29,31,34,40,42</sup> between 200 and 300 in two<sup>36,41</sup> and unclear for one paper.<sup>33</sup> SCFAs were mostly measured in faecal samples (*n* = 16),<sup>26–39,41,42</sup> in urine<sup>27</sup> and in serum<sup>40</sup> in each one article. The largest number of papers used gas chromatography (*n* = 7)<sup>26,27,30,31,37,41,42</sup> for sample analysis (Table S1). Details of each of the 17 papers, including the timing or definition of outcome, statistical analysis method and results are presented in Table 1.

#### 3.1.2 | Quality assessment


Based on the NOS, the risk of bias was categorised as low for nine papers,<sup>26,28,31,33–35,37–39</sup> medium for seven papers<sup>27,29,30,32,36,40,41</sup> and high for one paper.<sup>40</sup> The details of the results of the assessments are presented in Table S2. The criterion for ‘non-response rate’ was the least fulfilled (four out of 17 papers) among all criteria.

#### 3.1.3 | Synthesis of results

Results are summarised for each allergic disease in Tables 2 and 3.

### 3.2 | SCFAs and development of atopic dermatitis (Table 2, 10 papers)

Six papers assessed AD in early childhood (1–3 years),<sup>32,33,35,38,39,42</sup> while four papers assessed AD in later childhood (6, 8 or 13 years).<sup>28,30,31,36</sup> A significant decrease in the level (or proportion of children with high level) of any of the three main SCFAs



**FIGURE 1** PRISMA flow chart showing the results of the literature search and the selection of studies. SCFA, short chain fatty acids.

(acetate, propionate or butyrate) among cases were reported in five of the six papers for early AD (acetate in one study, propionate in two studies and butyrate in four studies).<sup>33,35,38,39,42</sup> Among these papers, one birth cohort study only found a difference in SCFAs at 1 year when AD was assessed (Sasaki et al.).<sup>38</sup> Analysis from a Singaporean birth cohort study (GUSTO study) reported that butyrate and propionate were decreased in children with atopic AD but not in non-atopic AD compared with controls, using longitudinal analysis with SCFA measurements at 3 weeks, 3, 6 and 12 months and adjusting for confounders (Ta et al.).<sup>39</sup> Two other studies using longitudinal analysis reported that there was a reverse association between the SCFA profile (butyrate and propionate) and AD at 6 months in a study using data from a randomised controlled trial (Wopereis et al.)<sup>42</sup> and at 12 months in a Korean birth cohort study (Lee et al.).<sup>33</sup>

Among the four papers investigating the effect of SCFAs on late AD, decrease in acetate and butyrate in cases was reported only in the paper by Cheng et al., using the data from the GUSTO study. This paper reported that low faecal butyrate at 3 weeks, 3 and 6 months were longitudinally associated with AD (adjusted odds ratio: adjOR 13.2, 95% CI 1.1–158.3).<sup>28</sup> Decrease in valerate measured in early childhood among cases was shown with AD at 8 or 13 years in two different birth cohort studies conducted in rural Sweden.<sup>30,31</sup>

### 3.3 | SCFAs and development of wheeze/asthma (Table 3, nine papers)

Of the nine papers that investigated the outcome of wheeze/asthma,<sup>26–31,34,36,40</sup> six reported decrease in one or more of the three main SCFAs among children who developed the disease,<sup>26–29,34,40</sup> while there was no difference shown in the remaining three papers. Acetate was decreased among cases in all four studies that assessed prenatal or early infancy (6 months or before) samples and the development of wheeze/asthma at 6 years or earlier.<sup>26,27,34,40</sup> Of the two papers that reported the association between maternal acetate, one assessed faecal samples in a RCT on prenatal Vit D supplementation (Lee-Sarwar et al.)<sup>34</sup> and reported that the relative concentration of acetate was decreased in children with asthma/wheeze plus sensitisation (odds ratio: OR 0.46, 95% CI 0.33–0.94 by 10% increase in acetate). The other study reported an association of maternal serum acetate in a hospital-based case control study with follow up among pregnant women who have asthma (Thorburn et al.).<sup>40</sup> None of the studies which measured acetate at 1 year or later or those assessing wheeze/asthma at 8 years or later reported any difference in acetate ( $n=6$ ).<sup>27–31,36</sup>

Decrease in butyrate or propionate during infancy among cases was reported in two and three out of eight papers,<sup>27–29</sup> respectively, that investigated the outcome up to 8 years. Of these papers, the paper from Arrieta et al. using data from a Canadian birth cohort study

TABLE 1 Detailed description of the studies that investigated the association between short chain fatty acids and development of allergic diseases.

| Author, Country, Year Study                                 | Sample size of case/control                                      | Sample type, analysis method        | SCFAs measured <sup>a</sup>  | Timing of outcome assessment and definition of outcome  | Statistical method   | Main results   |
|---|--|-------------------------------------|------------------------------|---|--|--|
| Sandin et al, Sweden 2009 (BAS study) <sup>37</sup>         | FA: 17/53, allergy: 10/19  | Faeces at 1 and 4 years, GC         | A, P, B, V, C, i-V, i-B, i-C | 4 years, sensitisation: SPT positive, FA: doctor diagnosis, allergy: positive SPT and AD, BA or FA  | Mann-Whitney<br>U-test   | No association between SCFA at 1 year and sensitisation at 4 years. Low levels of i-butyrate, i-valerate and valerate at 1 year were associated with FA at 4 years ( $p = .01$ , $p = .03$ and $p = .02$ , respectively), which remained after excluding those with FA at 1 year. Allergic children had higher acetate but lower i-butyrate at 4 years compared with non-allergic children ( $p = .02$ and $p = .04$ ), and a trend of lower i-valerate and valerate ( $p = .06$ and $p = .06$ ) of which only valerate remained after excluding children with FA at 1 year. |
| Gio-Batta et al., Sweden 2022 (BAS study) <sup>31</sup>     | AD: 28/33, FA: 28/33, BA: 19/33, RA: 28/33, sensitisation: 54/33 | Faeces at 1 year, GC                | A, P, B, V, C, i-V, i-B, i-C | 13 years, AD: reported symptoms in the last 12 months, FA: reported symptoms, BA: report of diagnosis or medication use, symptoms in the last 12 months plus aeroallergen sensitisation (SPT $\geq 3$ mm), ARC: symptoms in the last 12 months plus aeroallergen sensitisation, RA: BA or symptoms to aeroallergen exposure and sensitisation | Logistic regression (no adjustment)  | The concentration of valerate at 1 year was inversely associated with AD at 13 year (OR 0.6, 95% CI: 0.4–1.0, $p = .049$ ) and a trend for FA (OR 0.6, 95% CI: 0.4–1.0, $p = .057$ ). The proportion of faecal valerate at 1 year was inversely associated with AD and FA (OR 0.6, 95% CI: 0.4–1.0, $p = .046$ and OR 0.5, 95% CI: 0.3–0.9, $p = .03$ , respectively). No association between other SCFA and BA, ARC or RA.  |
| Vuillermin et al., Australia 2020 (BIS study) <sup>41</sup> | 57/240   | Faeces at 36 weeks of gestation, GC | A, P, B, V, C, i-V, i-B      | 1 year, FA: sensitisation (SPT > 2 mm) and positive food challenge test   | Unclear  | No difference.   |
| Sasaki et al., Switzerland 2022 (CARE study) <sup>38</sup>  | 27/39  | Faeces at 3, 6 and 12 months, HPLC  | A, P, B                      | Up to 1 year, AD: symptoms reported, diagnosis reported or made at clinical examination   | Mann-Whitney<br>U-test as continuous variable and chi-squared test as categorical variable | No difference in SCFAs as continuous variable. Children with AD were less likely to have high level of butyrate (>75 percentile cut-off at 18.86 $\mu\text{mol/g}$ ) at 12 months (11.5% vs 34.2%, $p = .04$ ). No difference in other SCFAs or at different time points.  |

(Continues)

TABLE 1 (Continued)

| Author, Country, Year Study                                   | Sample size of case/control                                    | Sample type, analysis method          | SCFAs measured <sup>a</sup>               | Timing of outcome assessment and definition of outcome  | Statistical method                                    | Main results   |
|---|--|---------------------------------------|---|---|---|--|
| Arrieta et al., Canada 2015 (CHILD study) <sup>27</sup>       | 13/13  | Faeces and urine, 3 and 12 months, GC | A, P, B, V, C, i-V, i-B                   | Up to 1 year, atopic wheeze: SPT $\geq 2$ mm and reported or clinician recorded wheeze at 1 year  | Mann-Whitney U-test                                   | Acetate higher in faeces of controls (14.13 $\pm$ 8.19 vs 7.77 $\pm$ 6.01 $\mu$ mol/g faeces, $p = .03$ ), no difference in propionate (2.07 $\pm$ 2.08 vs 1.06 $\pm$ 0.91, $p = .38$ ) or butyrate (0.29 $\pm$ 0.51 vs 0.47 $\pm$ 0.56, $p = .15$ ) at 3 months. At 1 year, faecal propionate, iso-butyrate, butyrate, iso-valerate, valerate but not acetate was higher in controls. No difference in urine. |
| Lee et al., Korea 2022 (COCOA study) <sup>33</sup>            | Number of samples: 110 (mild AD), 124 (moderate-severe AD)/112 | Faeces at 3-36 months, GC-MS          | A, P, B, V, i-V, i-B, methyl-valeric acid | Up to 3 year, AD: Hanifin and Rajka's criteria, every year from 6 months, SCORAD $> 25$ as moderate-severe  | SCFA-by-age z-score calculated using machine learning | Children with AD had highly matured SCFA profile before 12 months but delayed after 12 months compared with controls. Butyrate contributed more to the model than propionate.  |
| Park et al., Korea 2020 (COCOA study) <sup>35</sup>           | 12 (transient AD), 12 (persistent AD)/33                       | Faeces at 6 months, GC-MS             | A, P, B, V                                | Up to 2 years, AD: Hanifin and Rajka's criteria, transient AD: only 6 months, persistent AD: 6 months and 2 years   | Kruskal-Wallis test and the Mann-Whitney U-test       | Butyrate and valerate levels were lower in infants with transient AD than in healthy controls ( $p = .011$ and $p = .004$ , respectively) and than in the persistent AD group ( $p = .020$ and $p = .008$ , respectively). No difference in acetate or propionate.   |
| Arrieta et al., Ecuador 2018 (ECUAVIDA study) <sup>26</sup>   | 27/70  | Faeces at 3 months, GC                | A, P, B, V, C, i-V, i-B                   | 5 years, atopic wheeze: reported wheeze and sensitisation (SPT $\geq 3$ mm)   | Mann-Whitney U-test                                   | Decrease in acetate ( $< 0.05$ ) and increase in caproate concentration ( $< 0.01$ ) in children who developed atopic wheeze. No difference in butyrate, propionate, iso-butyrate or valerate.   |
| Gio-Batta et al., Sweden 2020 (FARMFLORA study) <sup>30</sup> | 4 (AD), 2 (ARC), 3 (BA)/30                                     | Faeces at 3 years, GC                 | A, P, B, V, C, i-V, i-B                   | 8 years, AD: William's criteria or symptoms $> 6$ months in the last 12 months, BA: reported symptoms with response to treatment, positive methacholine challenge or reversible bronchial obstruction by beta 2 agonist, FA: symptoms and reaction to exposure or at OFC, ARC: symptoms to exposure with sensitisation. | Mann-Whitney U-test                                   | Children with AD had lower median concentration of valeric acid compared with controls (0.5 vs. 2.3 $\mu$ mol/g, $p = .007$ ), which remained among only non-farm children. No other SCFA was associated with any of the outcomes.   |

TABLE 1 (Continued)

| Author, Country, Year Study                              | Sample size of case/control  | Sample type, analysis method                     | SCFAs measured <sup>a</sup>                             | Timing of outcome assessment and definition of outcome   | Statistical method   | Main results  |
|--|--|--|---|--|--|---|
| Ta et al., Singapore 2020 (GUSTO study) <sup>39</sup>    | 14 (non-atopic AD), 19 (atopic AD)/30  | Faeces at 3 weeks, 3, 6, and 12 months, LC-MS-MS | A, P, B, V, C, i-V, i-B, 2-methyl- and 4-methylbutyrate | Up to 3 years, AD: reported diagnosis, atopic: SPT $\geq 3$ mm   | Linear mixed-model and general linear model, adjusting for gender, birth order, mode of delivery, breastfeeding till 6 months, antibiotics at labour and family of atopic history                      | Lower concentrations of acetate, butyrate and propionate in atopic AD (adj $p < .05$ ), but not in non-atopic AD at all time points. Longitudinal analysis showed decreased butyrate and propionate associated with atopic AD (adj $p < .05$ ).   |
| Cheng et al., Singapore 2022 (GUSTO study) <sup>28</sup> | AD: 35/32, wheeze: 19/43, recurrent wheeze: 9/53, inhalant sensitisation: 45/19, food sensitisation: 17/46, AD and wheeze: 16/30 | Faeces at 3 weeks, 3, 6 and 12 months, LC-MS-MS  | A, P, B, V, i, i-V, i-B, 2-methyl- and 4-methylbutyrate | Up to 8 years, AD: reported diagnosis, wheeze: reported wheeze and use of nebuliser, recurrent wheeze: wheeze more than once, sensitisation: SPT $\geq 3$ mm | Logistic regression and Generalised Linear Mixed Models for longitudinal analysis, adjusting for gender, presence of siblings, mode of delivery, family history of atopic diseases and feeding pattern | Lower butyrate ( $\leq 25$ percentile) at 3 and 6 months associated with increased risk of AD [adjOR (95% CI) = 58.3 (1.5–2315.7) and 41.9 (1.0–1678.9), respectively] compared to children with higher butyrate levels ( $\geq 75$ percentile). A similar trend for lower acetate at 6 months [adjOR (95% CI) = 18.5 (1.0–336.2)] ( $p < .05$ ). Lower caproate at 12 months increased the risk of wheeze compared with children with higher levels [adjOR (95% CI) = 28.1 (1.2–650.3)]. Longitudinal analysis (3 weeks, 3 and 6 months) showed that lower butyrate levels increased the risk of wheezing [adjOR (95% CI) = 14.6 (1.2–189.7)], AD [adjOR (95% CI) = 13.2 (1.1–158.3)], food sensitisation [adjOR (95% CI) = 12.3 (1.3–115.0)] and combined outcomes of both wheezing and AD [adjOR (95% CI) = 22.6 (1.3–382.7)]. Low levels of propionate levels were associated with recurrent wheezing [adjOR (95% CI) = 7.4 (1.2–44.2)] for all 4 time points (Week 3, Months 3, 6 and 12). |

(Continues)

TABLE 1 (Continued)

| Author, Country, Year Study  | Sample size of case/control  | Sample type, analysis method     | SCFAs measured <sup>a</sup> | Timing of outcome assessment and definition of outcome  | Statistical method   | Main results  |
|--|--|----------------------------------|-----------------------------|---|--|---|
| Roduit et al., Austria, Switzerland, France, Germany and Finland, 2019 (PASTURE study) <sup>36</sup>             | BA: 33/244, AR: 25/240, FA: 33/257, AD: 140/160, inhalant sensitisation: 11/166, food sensitisation: 102/174 | Faeces at 1 years, HPLC          | A, P, B                     | Up to 6 years, BA: reported diagnosis or at least 2 episodes of obstructive bronchitis in the year 4,5,6. FA: reported diagnosis, AD: reported diagnosis and/or SCORAD at 1 year, AR: reported diagnosis or symptoms, sensitisation: Serum sIgE measured at 6 years | Fisher's exact test (proportion) and logistic regression model (binary) adjusted for centre, farmer, sex, parent allergy, mode of delivery, breastfeeding and siblings | Proportion of children sensitised was lower among children with high levels of butyrate (26.7% vs 56.3% >95th percentile; >26.88 µmol/g) and propionate (20.0% vs 56.7%, >32.87 µmol/g), no association with acetate (14.3% vs 11.8%, >114.67 µmol/g). There was no association between the SCFAs and AD, AR, FA or BA. Children with SCFA in higher categories (>95th percentile vs lower) of butyrate or propionate had adjusted OR: 0.25 (95% CI, 0.08–0.82) and 0.20 (95% CI, 0.05–0.74), respectively for sensitisation. |
| Depner et al., Austria, Switzerland, France, Germany and Finland, 2020 (PASTURE study) <sup>29</sup>             | 44/94  | Faeces at 1 years, HPLC          | A, P, B                     | Up to 6 years, BA: reported diagnosis or at least 2 episodes of obstructive bronchitis in the year 4,5,6.   | Logistic regression (no adjustment)  | Children with butyrate in the upper quartiles, had OR 0.28 (95% CI 0.09–0.91, <i>p</i> = .034) of BA compared with those in the lowest quartile.  |
| Wopereis et al., Australia, England, and Ireland, 2018 (PATCH trial, RCT among high-risk children) <sup>42</sup> | 52/ 86   | Faeces at 4, 12 and 26 weeks. GC | A, P, B, V, i-B             | Up to 18 months, modified Hanifin and Rajka criteria  | Principal response curves using ethnicity, feeding group, and siblings as covariates, with Monte Carlo permutation tests   | Infants with AD had decreased lactate and increased propionate and butyrate at 12 weeks, which reversed at 26 weeks, where infants with AD had increased lactate and decreased propionate and butyrate.   |
| Kim et al., the Netherlands 2015, (the Panda study, RCT among high-risk children) <sup>32</sup>                  | 17/16  | Faeces at 3 months, NMR          | A, P, B                     | Up to 2 years, reported AD (with confirmation by a diagnosis in a number of cases)  | ANOVA and orthogonal partial least squares-discriminant analysis (OPLS-DA)   | No difference between case and control by ANOVA: Acetate 0.48 (0.42) versus 0.52 (0.39), Propionate 0.08 (0.09) versus 0.10 (0.08), <i>n</i> -butyrate 0.10 (0.10) versus 0.10 (0.11), total SCFA 0.65 (0.56) versus 0.72 (0.46), concentrations are in arbitrary units (standard deviation). But small difference in butyrate, acetate detected by OPLS-DA.  |



TABLE 1 (Continued)

| Author, Country, Year Study   | Sample size of case/control   | Sample type, analysis method      | SCFAs measured <sup>a</sup> | Timing of outcome assessment and definition of outcome   | Statistical method   | Main results   |
|---|---|-----------------------------------|-----------------------------|--|--|--|
| Lee-Sarwar et al., USA 2019, (VDAART study, RCT) <sup>3,4</sup>                                 | BA: 70/80, sensitisation: 38/42, AR: 54/81, atopic BA: 17/63, BA and AR: 33/102 | Faeces, third trimester, LC-MS-MS | A, P, B                     | Up to 6 years, BA: reported diagnosis, recurrent wheeze and medication use. Sensitisation: serum sIgE > 0.35 kU/L, AR: reported diagnosis, asked every 3 months and at annual in person visits up to 6 years | Logistic regression, adjusted for early pregnancy BMI and breastfeeding. | None of the SCFAs were associated with BA, sensitisation or AR. Relative acetate inversely associated with atopic BA (OR 0.46, 95% CI 0.22–0.94, $p = .036$ , for a 10% increase).   |
| Thorburn et al., Australia 2015, hospital-based case control study with follow-up <sup>40</sup> | Total sample size 40  | Serum, late phase pregnancy, NMR  | A, P, B                     | Up to 1 year, two or more general practitioner visits for cough or wheeze, reported wheeze   | Chi-squared test   | Children born to mothers (without BA) with acetate lower than median (0.05315 mM) were more likely to require two or more general practitioner visits for cough or wheeze and a trend toward increased parent-reported wheeze. No association when mother had BA or for other SCFAs. |

<sup>a</sup>Individual SCFAs are abbreviated as A: acetate, P: propionate, B: butyrate, V: valerate, C: caproate, i-B: iso-butyrate, i-V: iso-valerate, i-C: iso-caproate. BCFAs: branched short chain fatty acids.

Abbreviations: AD, atopic dermatitis/eczema; adjOR, adjusted odds ratio; AR, allergic rhinitis (including hay fever); ARC, allergic rhino-conjunctivitis; BA, asthma; FA, food allergy; GC, gas chromatography; GC-MS, gas chromatography mass spectroscopy; HPLC, high-performance liquid chromatography; LC-MS-MS, liquid chromatography tandem mass spectrometry; NMR, nuclear magnetic resonance spectroscopy; OR, odds ratio; SPT, skin prick test.

TABLE 2 Summary of papers that reported the association between short chain fatty acids and atopic dermatitis later in life.

|                            |                    | Timing of outcome (atopic dermatitis) assessment             |   |  |   |   |
|----------------------------|--------------------|--|---|--|---|---|
|                            |                    | 1 year   | 18 months   | 2–3 years  | 6–8 years   | 13 years  |
| Timing of SCFA measurement | Newborn (<1 month) |  |   | Ta 2020 <sup>39</sup> ▼ acetate, propionate, butyrate  | Ta 2020 <sup>39</sup> ▼ butyrate, propionate<br>X acetate   | Cheng2022 <sup>4,28</sup> X all<br>Cheng2022 <sup>4,28</sup> ▼ acetate, butyrate X others                               |
|                            | 3–6 months         | Sasaki 2022 <sup>38</sup> X acetate, propionate, butyrate    | Woperies 2018 <sup>e,38</sup> propionate, butyrate △ at 12 weeks ▼ at 26 weeks X valerate, iso-butyrate | Park 2020 <sup>b,35</sup> ▼ valerate X acetate, propionate Ta 2020 <sup>39</sup> ▼ acetate, propionate, butyrate<br>Kim 2015 <sup>c,32</sup> X acetate, propionate, butyrate | Lee 2022 <sup>e,33</sup> mature pattern until 12 months and delayed after 12 months                           | Cheng2022 <sup>4,e,28</sup> ▼ butyrate X others   |
|                            | 12 months          | Sasaki 2022 <sup>a,38</sup> ▼ butyrate X acetate, propionate |   | Ta 2020 <sup>39</sup> ▼ acetate, propionate, butyrate  | Cheng2022 <sup>4,28</sup> X all Roduit 2019 <sup>3,6</sup> X acetate, propionate, butyrate                    | Gio-Batta 2022 <sup>31</sup> ▼ valerate X acetate, propionate, butyrate, iso-butyrate, valerate, caproate, iso-caproate |
|                            | 3 years old        |  |   |  | Gio-Batta 2020 <sup>30</sup> ▼ valerate X acetate, propionate, butyrate, iso-butyrate, caproate, iso-caproate |   |

Note: Levels/concentrations, relative abundance or proportion of individuals with high levels observed in cases were ▼: decreased, △: increased or X: not different compared with controls. For the purposes of this review, *p*-value <.05 was considered as a significant association. SCFAs were measured in faecal samples if not stated otherwise.

<sup>a</sup>SCFA measurement and outcome assessment are done at the same timing.

<sup>b</sup>Association was only found with transient AD and not with persistent AD.

<sup>c</sup>Small decrease in SCFA when analysed by orthogonal partial least squares-discriminant analysis.

<sup>d</sup>SCFAs (acetic, propionic, butyric, iso-butyric, valeric, isovaleric, 2-methylbutyric, caproic and 4-methylvaleric acids) were assessed in this study. No difference between case and control if not listed here.

<sup>e</sup>Results from longitudinal analysis using multiple time points during this period. Otherwise, results are from individual analyses between SCFAs measured at one or two timepoints in each cell.

TABLE 3 Summary of papers that reported the association between short chain fatty acids and wheeze/asthma, food allergy, allergic rhinitis and any allergy.

| A. Wheeze/asthma     |  | Timing of outcome assessment   |   |  |  |
|----------------------|--|--|---|--|--|
| SCFA measurement     | 1 year   | 5–6 years  | 8 years   | 13 years   |  |
| Prenatal (maternal)  | Thorburn 2015 (serum) <sup>40</sup> ▼ acetate <sup>a</sup><br>X butyrate, propionate                                 | Lee-Sarwar <sup>34</sup> ▼ acetate X butyrate,<br>propionate   |   |  |  |
| Newborn (<1 month)   |  |  | Cheng 2022 <sup>c,28</sup> ▼ propionate X others  | Cheng 2022 <sup>c,d,28</sup><br>▼ butyrate<br>(3 weeks–6 months),<br>▼ propionate<br>(3 weeks–12 months)   |  |
| 3–6 months           | Arrieta 2015 <sup>27</sup> ▼ acetate X butyrate,<br>propionate, iso-butyrate, valerate,<br>iso-valerate, caproate    | Arrieta 2018 <sup>26</sup> ▼ acetate △<br>caproate X butyrate, iso-<br>butyrate, propionate, valerate                            |   |  |  |
| 12 months            | Arrieta 2015 <sup>27 b</sup> ▼ propionate,<br>butyrate, iso-butyrate, valerate,<br>iso-valerate X acetate            | Roduit 2019 <sup>36</sup> X acetate,<br>propionate, butyrate Depner<br>2020 <sup>29</sup> ▼ butyrate X acetate,<br>propionate    | Cheng 2022 <sup>c,28</sup> ▼ propionate, caproate<br>X others   | Gio-batta 2022 <sup>31</sup> X<br>acetate, propionate,<br>butyrate, iso-<br>butyrate, valerate,<br>iso-valerate,<br>caproate,<br>iso-caproate                |  |
| 3 years              |  |  | Gio-batta 2020 <sup>30</sup> X acetate, propionate, butyrate, iso-butyrate,<br>valerate, iso-valerate, caproate, iso-caproate |  |  |
| B. Food allergy      |  | Timing of outcome assessment   |   |  |  |
| SCFA measurement     | 1 year   | 4 years  | 6 years   | 13 years   |  |
| Prenatal (maternal)  | Vuillermin 2020 <sup>41</sup> X acetate, propionate,<br>butyrate, valerate, iso-butyrate, iso-<br>valerate, caproate |  |   |  |  |
| 12 months            |  | Sandin 2009 <sup>37</sup> ▼ valerate, iso-valerate,<br>iso-butyrate X acetate, propionate,<br>butyrate                           | Roduit 2019 <sup>36</sup> X acetate,<br>propionate, butyrate  | Gio-Batta 2022 <sup>31</sup> ▼ valerate, propionate <sup>e</sup><br>△ butyrate <sup>e</sup> X acetate, iso-butyrate,<br>iso-valerate, caproate, iso-caproate |  |
| C. Allergic rhinitis |  | Timing of outcome assessment   |   |  |  |
| SCFA measurement     | 6 years  | 8 years  | 13 years  |  |  |
| Prenatal (maternal)  | Lee-Sarwar 2019 <sup>34</sup> X acetate, propionate, butyrate  |  |   |  |  |
| 12 months            | Roduit 2019 <sup>36</sup> X acetate, propionate, butyrate  |  |   | Gio-Batta 2022 <sup>31</sup> X acetate, propionate, butyrate,<br>valerate, iso-butyrate, iso-valerate, caproate,<br>iso-caproate                             |  |
| 3 years              |  | Gio-Batta 2020 <sup>30</sup> X acetate, propionate, butyrate,<br>valerate, iso-butyrate, iso-valerate, caproate,<br>iso-caproate |   |  |  |

(Continues)

TABLE 3 (Continued)

| D. Any allergy       | Timing of outcome assessment  |   |                                   |   |
|----------------------|---|---|-----------------------------------|---|
| SCFA measurement     | 4 years   | 6 years   | 8 years                           | 13 years  |
| Prenatal (maternal)  |   | Lee-Sarwar 2019 <sup>34</sup> X acetate, propionate, butyrate |                                   |   |
| Newborns (<1 months) |   |   | Cheng 2022 <sup>c, 28</sup> X all | Cheng 2022 <sup>c, d, 28</sup> ▼ butyrate (3 weeks–6 months, for food sensitisation or BA plus AD) X others   |
| 3–6 months           |   |   | Cheng 2022 <sup>c, 28</sup> X all |   |
| 12 months            | Sandin 2009 <sup>37</sup><br>X acetate, propionate, butyrate, valerate, caproate, iso-butyrate, iso-valerate, iso-caproate                                      | Roduit 2019 <sup>36</sup> ▼ butyrate, propionate X acetate    | Cheng 2022 <sup>c, 28</sup> X all | Gio-Batta 2022 <sup>31</sup><br>X acetate, propionate, butyrate, valerate, caproate, iso-butyrate, iso-valerate, iso-caproate (for respiratory allergy) |
| 4 years              | Sandin 2009 <sup>b, 37</sup><br>▼ iso-butyrate, Δ acetate X propionate, butyrate, valerate, caproate, iso-valerate, iso-caproate for sensitisation plus disease |   |                                   |   |

Note: Levels/concentrations, relative abundance or proportion of individuals with high levels observed in cases were ▼: decreased, Δ: increased or X: not different compared with controls. For the purposes of this review, *p*-value <.05 was considered as a significant association. SCFAs were measured in faecal samples if not stated otherwise.

<sup>a</sup>Association was shown only when the mother had asthma.

<sup>b</sup>SCFA measurement and outcome assessment are done at the same timing.

<sup>c</sup>9 SCFAs (acetic, propionic, butyric, iso-butyric, valeric, isovaleric, 2-methylbutyric, caproic and 4-methylvaleric acids) were assessed in this paper. No difference between cases and controls if not listed here.

<sup>d</sup>Results from longitudinal analysis using multiple time points during this period. Otherwise, results are from individual analyses between SCFAs measured at one or two timepoints in each cell.

<sup>e</sup>These associations were shown only for some allergens when the stratified by allergens.

(CHILD study) only reported a decrease in cases when the measurement and outcome assessment was done at the same timepoint.<sup>27</sup> Roduit et al. analysed data from more than 300 children in a multinational European birth cohort study (PASTURE study) and reported that children with high level (>95th percentile) of butyrate or propionate at 1 year had lower proportion of asthma at 6 years, although these associations were not statistically significant.<sup>36</sup> However, Depner et al. reported a statistically significant decrease in butyrate among cases in a different analysis using a subset of the same data (upper quartiles vs lowest quartile, OR 0.28, 95% CI 0.09–0.91).<sup>29</sup> Analysis of the GUSTO study reported that propionate was associated with children with recurrent wheezing longitudinally (lowest vs highest quartile, adjOR 7.4, 95% CI 1.2–44.2) and at all time points (3 week, 3, 6 and 12 months).<sup>26</sup> This study also reported a decrease in caproate at 12 months to be associated with the development of wheeze/asthma up to 8 years (adjOR 28.1, 95% CI 1.2–650.3).<sup>26</sup>

### 3.4 | SCFAs and development of food allergy (Table 3, four papers)

None of the studies found association between food allergy (assessed between 1 and 13 years) and the three main SCFAs.<sup>31,36,37,41</sup> Two papers (Sandin et al. and Gio-batta et al.) using data from the same Swedish birth cohort study (BAS study) reported decreased level of valerate at 1 year in cases with food allergy at 4 years<sup>37</sup> and at 13 years.<sup>31</sup>

### 3.5 | SCFAs and development of allergic rhinitis (Table 3, four papers)

None of the four studies found association between allergic rhinitis and the three main or other SCFAs.<sup>30,31,34,36</sup>

### 3.6 | SCFAs and development of atopic sensitisation (Table 3, four papers)

Of the four papers,<sup>28,34,36,37</sup> analysis of the PASTURE study by Roduit et al. reported that children with high level of butyrate or propionate at 1 year were less likely to be sensitised at 6 years (>95th percentile vs lower, adjOR 0.25, 95% CI 0.08–0.82 for butyrate and 0.20, 95% CI 0.05–0.74 for propionate).<sup>36</sup> Decrease in butyrate was longitudinally (3 weeks, 3 and 6 months) associated with food sensitisation at 8 years (lowest vs. highest quartile adjOR 12.3, 95% CI 1.3–115.0) in the analysis by Cheng et al. using data from the GUSTO study.<sup>28</sup>

### 3.7 | SCFAs and development of any allergy (Table 3, three papers)

Three papers assessed the association between SCFAs and a combined outcome, each using a different definition.<sup>28,31,37</sup> A Swedish

birth cohort study (BAS study) reported increase in acetate and decrease in iso-butyrate in children who were sensitised and had any allergic disease at 4 years, although only in samples assessed at 4 years and not at 1 year (Sandin et al.).<sup>37</sup> Cheng et al. reported decreased butyrate between 3 weeks and 6 months for children with both AD and asthma at 8 years (lowest vs highest quartile adjOR 22.6, 95% CI 1.3–382.7).<sup>28</sup>

## 3.8 | SCFAs and pre-existing allergic diseases

### 3.8.1 | Study characteristics

All articles in this category arose from unique studies, and of the total 20 studies,<sup>43–62</sup> most were case control studies ( $n=15$ ).<sup>43,46–51,53,55–61</sup> The number of participants who had SCFAs measured and compared were less than 50 in seven studies,<sup>44,47,48,52,53,60,62</sup> between 50 and 100 in 10 studies,<sup>43,45,50,51,55–59,61</sup> and between 100 and 150 in three studies.<sup>46,49,54</sup> Most studies were carried out in children, with four studies in infants (1 year or younger),<sup>44,45,55,57</sup> and eight in children between 1 and 14 years.<sup>43,46–50,56,58</sup> SCFAs were measured in faecal samples in the majority of studies ( $n=14$ )<sup>43–49,51–53,55,58,59,62</sup> and gas chromatography ( $n=7$ , Table S1) was most often used for sample analysis.<sup>43–45,47,49,52,55</sup> The largest number of papers investigated the outcome of IgE-mediated food allergy ( $n=9$ ). Details of each of the 20 papers are presented in Table 4.

### 3.8.2 | Quality assessment

Based on the NOS, 14 papers were assessed as having medium risk of bias,<sup>43,46,47,49,50,52–54,57–62</sup> five were low risk,<sup>44,45,48,55,56</sup> and one with high risk.<sup>51</sup> The details of the assessments are presented in Table S3. The criterion for “representativeness of the cases” was the least fulfilled (four out of 20 articles) among all criteria.

### 3.8.3 | Synthetisation of results (Table 5)

## 3.9 | SCFAs and pre-existing IgE-mediated food allergy (nine papers)

Of the eight studies in infants or children with IgE-mediated food allergy,<sup>44,46,48–50,55,56,58</sup> decrease in two or more of the three main SCFAs or total SCFA among cases were reported in five studies.<sup>46,48–50,56</sup> Salivary SCFAs were assessed in two studies of children with peanut allergy in the USA, (Ho et al. and Zhang et al.), of which one study reported decreased acetate, propionate and butyrate in cases (Ho et al.)<sup>50</sup> and the other found a trend but not a statistically significant difference (Zhang et al.).<sup>58</sup> One Chinese study (Tian et al.) reported decrease in all three main SCFAs measured in serum among children with IgE-mediated food allergy.<sup>56</sup>

TABLE 4 Detailed description of the studies that investigated the association between short chain fatty acids and pre-existing allergic diseases.

| Author, country, year, study design                                       | Sample size of cases/controls         | Sample type, analysis method      | SCFA measured <sup>a</sup> | Outcome, definition of outcome   | Statistical analysis method  | Main results  |
|---|---------------------------------------|-----------------------------------|----------------------------|--|--|---|
| Ivashkin et al., Russia 2019, case control study <sup>51</sup>            | 24 (atopic BA), 20 (non-atopic BA)/17 | Faeces, gas-liquid chromatography | A, P, B                    | BA: unclear  | Mann-Whitney U-test  | Acetate, $5.87 \pm 0.22$ mg/g (healthy), $1.31 \pm 0.59$ (atopic asthma), $1.41 \pm 0.59$ (non-atopic asthma).<br>Propionate $1.77 \pm 0.08$ , $0.56 \pm 0.33$ , $0.64 \pm 0.36$ . Butyrate $1.73 \pm 0.09$ , $0.39 \pm 0.23$ , $0.57 \pm 0.23$ , all $p < .001$ .  |
| Jung et al., Korea, 2013, case control study <sup>61</sup>                | 39/26                                 | Serum, NMR                        | A                          | BA: specialist diagnosis based on history and evidence of reversible airway obstruction  | Mann-Whitney U-test  | Acetate was decreased in cases compared with controls ( $p < .0001$ ).  |
| Roessler et al., Germany 2012, within an RCT <sup>52</sup>                | 15/15                                 | Faecal water, GC                  | A, P, B, V, C              | AD: more than 10 points according to the atopy-score of Diepgen17, or flexural eczema or pruritis for at least 12 months, a SCORAD score of 5–30 | Mann Whitney U-test  | For samples taken after placebo: <i>n</i> -Caproate higher in healthy subjects $1.0 \pm 0.7$ vs AD $0.4 \pm 0.6$ , no difference in acetate, propionate, iso-Butyrate, <i>n</i> -Butyrate, iso-Valerate, <i>n</i> -Valerate or total SCFA.  |
| Wang et al., Taiwan 2022, hospital-based case control study <sup>57</sup> | 47/47                                 | Breastmilk, GC-MS                 | A, B                       | AD (of child): Hanifin and Rajka, objSCORAD for severity   | independent <i>t</i> -test or Mann-Whitney U-test, Stepwise multiple regression analysis | Total SCFA and acetate were lower at each $716.0 \pm 52.7$ vs $1096.2 \pm 122.5$ $\mu$ M and $468.3 \pm 46.8$ vs $857.3 \pm 114.7$ $\mu$ M in the breastmilk of exclusively breastfeeding mothers whose child was AD compared with control ( $p = .002$ , $.005$ ) respectively. No difference in butyrate level ( $247.7 \pm 18.1$ vs $238.9 \pm 23.0$ $\mu$ M; $p = .646$ ). When compared by lowest versus highest quartile, OR was 12, 95% CI 2.7–53.3, $p = .001$ for acetate and 10.52, 95% CI 2.27–48.76, $p = .003$ for SCFA. After adjustment for age, sex, parental allergy history, MUFA, palmitate and SCFA levels, acetate levels were correlated with AD, a OR 0.9980 (0.9964–0.9996), $p = .015$ . Level of acetate and total SCFA negatively correlated with objective SCORAD score ( $p = .013$ and $0.022$ ). |
| Song et al., Korea 2016, hospital-based case control study <sup>53</sup>  | 12/12                                 | Faeces, GC-MS                     | A, P, B                    | AD: SCORAD   | Unclear  | Butyrate and propionate increased in control compared with AD. No significant differences in acetate.   |

TABLE 4 (Continued)

| Author, country, year, study design   | Sample size of cases/controls          | Sample type, analysis method | SCFA measured <sup>a</sup> | Outcome, definition of outcome  | Statistical analysis method  | Main results  |
|---|--|------------------------------|----------------------------|---|--|---|
| Berni Canani et al., Italy 2016, within an intervention study <sup>44</sup>           | 19/20                                  | Faeces, GC                   | B                          | IgE-mediated cow's milk FA: history, positive DBPCFC and positive sIgE  | Nonparametric Kruskal-Wallis <i>H</i> -test (post hoc Tukey Kramer tests; Bonferroni multiple test correction) | No difference in butyrate between control vs cases at baseline. Among cases, children who became tolerant 6 months later had higher butyrate level than those who remained allergic at the time (12.52 ± 0.32 mmol/kg vs 10.32 ± 0.3 mmol/kg, <i>p</i> = .0032, Welch's <i>t</i> -test).  |
| Thompson-Chagoyan et al., Spain 2011, hospital-based case control study <sup>55</sup> | 46/46                                  | Faeces, GC                   | A, P, B, BCFA, i-C         | IgE-mediated cow's milk FA: history, positive SPT/sIgE and positive DBPCFC  | Mann-Whitney <i>U</i> -test  | Concentration of butyrate and BCFA were higher in cases compared with controls. The percentages of butyrate 6.7 (0.0–30.2) versus 1.8 (0.0–37.1); <i>p</i> < .05 and BCFA 3.1 (0.0–14.7) vs. 1.2 (0.0–7.4); <i>p</i> < .01 were also higher in cases compared with controls.  |
| Dong et al., China 2018, hospital-based case control study <sup>48</sup>              | 6/4                                    | Faeces, HPLC                 | A, P, B, i-B, lactate      | IgE-mediated cow's milk FA: history, positive SPT/sIgE and positive OFC   | Unclear  | Total SCFA was increased in controls compared with cases (221.33 vs 255.95 mmol/kg), no difference in individual SCFAs  |
| Goldberg et al., Israel 2020, hospital-based case control study <sup>49</sup>         | 84/31                                  | Faeces, GC                   | A, P, B                    | IgE-mediated FA: history of reaction or positive OFC in the past year and positive SPT (milk, peanut, sesame and tree nuts) | ANOVA followed by pairwise <i>t</i> -test and FDR correction.  | Lower concentrations in cases compared with controls for acetate ( <i>q</i> < 0.001) butyrate ( <i>q</i> < 0.001) and propionate ( <i>q</i> < 0.01).  |
| Ho et al., USA 2021, hospital-based case control study <sup>50</sup>                  | 49/39 (atopic and non-atopic controls) | Saliva, LC-MS                | A, B, P                    | IgE-mediated peanut allergy: positive OFC or reaction and sensitisation (SPT > 3 mm and/or sIgE ≥ 0.35 kUA/L)               | Mann-Whitney <i>U</i> -test  | Subjects with peanut allergy had significantly reduced salivary acetate, butyrate, and propionate levels compared with the healthy controls (median acetate level = 153,000 ng/mL [IQR 95,950–218,000 ng/mL] vs 229,000 ng/mL [IQR = 129,000–32,000 ng/mL] [ <i>p</i> = .013]; median butyrate level = 2930 ng/mL [IQR = 1540–5225 ng/mL] vs 5530 ng/mL [IQR = 3350–9290 ng/mL] [ <i>p</i> = .001]; and median propionate level 35,500 ng/mL [IQR 16,550–59,800 ng/mL] vs 49,900 ng/mL [32,900–75,600 ng/mL] [ <i>p</i> = .007], respectively). No difference between atopic controls without FA vs healthy controls. |

(Continues)

TABLE 4 (Continued)

| Author, country, year, study design  | Sample size of cases/controls             | Sample type, analysis method | SCFA measured <sup>a</sup>                    | Outcome, definition of outcome  | Statistical analysis method                                | Main results  |
|--|---|------------------------------|---|---|--|---|
| De Filippis et al., Italy 2021, hospital-based case control study <sup>46</sup>  | 55 (FA), 30 (RA)/29                       | Faeces, GC-MS                | B, P  | IgE-mediated FA: sensitised and symptoms to food, RA: sensitised to one or more aeroallergens (pollens, house dust mite, dog) | Pairwise Wilcoxon test                                     | Butyrate lower in FA versus control ( $p < .001$ ) and RA versus control ( $p < .001$ ) but not different between FA vs RA. Propionate lower in FA vs control ( $p < .001$ ), RA vs control ( $p < .01$ ) and RA vs FA ( $p = .03$ ).   |
| Tian et al., China 2022, hospital-based case control study <sup>56</sup>         | 40/40                                     | Serum, HPLC                  | A, P, B                                       | IgE-mediated FA: history, positive SPT and sIgE   | Mann-Whitney U-test  | Serum butyrate, acetate and propionate were lower in cases compared with controls (each $p < 0.001$ ).  |
| Zhang et al., USA 2022, hospital-based case control study <sup>58</sup>          | 38 (high threshold), 13 (low threshold)/8 | Saliva and faeces, LC-MS     | A, P, B                                       | IgE-mediated peanut allergy: positive DBPCFC  | Unclear  | The respective mean (SD) levels of acetate, butyrate and propionate were 4977.3 (2765.2), 33.6 (52.5), and 602.0 (349.0) in saliva and 425,249.8 (242,990.6), 158,865.5 (118,878.8), and 243,907.6 (128,934.9) in faeces. Salivary SCFAs trended highest in the controls compared with the cases, but the differences were not significant, and there were no significant differences between groups for faecal SCFA. |
| Bao et al., USA 2021, observational study <sup>62</sup>                          | 23/13                                     | Faeces, GC-MS                | A, B, P, V, C, i-B, i-V, 2-methylbutyric acid | IgE-mediated FA: positive OFC   | Wilcoxon's rank-sum tests with multiple testing adjustment | No difference in any of the SCFAs between FA and non-FA.  |
| Diaz et al., Spain 2018, hospital-based case control study <sup>47</sup>         | 17/10                                     | Faeces, GC                   | A, P, B, i-B, i-V                             | Non-IgE cow's milk allergy: history, negative SPT and/or IgE and positive OFC   | Mann-Whitney U-test  | There were no significant differences in acetate, butyrate, propionate levels between cases and controls, but a trend of increase in butyrate in cases (17.59 (12.74–21.41) versus 12.88 (6.14–14.3), $p = .06$ ). BCFAs (Iso-butyric acid and iso-valeric acid) was higher in cases than in control ( $p = .03$ ), 5.13 (3.08–6.52) versus 2.59 (1.94–3.37) $\mu\text{mol/g}$ .                                      |
| Berni Canani et al., Italy 2018, hospital-based case control study <sup>43</sup> | 46/23                                     | Faeces, GC                   | B   | Non-IgE mediated cow's milk allergy: clinical history, SPT and/or sIgE and DBPCFC   | Non-parametric Kruskal-Wallis and pairwise Wilcoxon tests  | Cases had lower butyrate concentration than controls. Butyrate highest in extensively hydrolysed casein formula (EHCF) plus <i>Lactobacillus rhamnosus</i> GG treated > healthy control or EHCF treated > untreated (at diagnosis).   |



TABLE 4 (Continued)

| Author, country, year, study design   | Sample size of cases/controls | Sample type, analysis method        | SCFA measured <sup>a</sup>    | Outcome, definition of outcome   | Statistical analysis method   | Main results  |
|---|-------------------------------|-------------------------------------|-------------------------------|--|---|---|
| Zhou et al., China 2021, hospital-based case control study <sup>60</sup>                          | 18/17                         | Faeces, GC-MS                       | A, P, B, V, i-B, i-V          | AR: History of reaction in the past year, sensitisation by positive SPT or sIgE >3.5Ku/L   | SCFA levels compared individually by ANOVA followed by pairwise t-test and FDR correction | Acetate, propionate and butyrate concentrations were lower in cases compared with controls.   |
| Zhou et al., China 2021, hospital-based case control study <sup>59</sup>                          | 36/36                         | Serum, HPLC                         | A, P, B                       | AR: International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis  | Student t-test or Mann-Whitney U-test   | Acetate, propionate and butyrate concentrations were lower in cases compared with controls.   |
| Böttcher et al., Sweden 2000 (BAS study) <sup>45</sup>  | 25/47                         | Faeces, GC                          | A, P, B, V, C, i-B, i-V, i-C  | Allergy: positive SPT to at least one allergen and allergic symptoms   | Mann-Whitney U-test   | Controls had higher levels of propionate, butyrate, iso-butyrate, iso-valerate and valerate levels compared with cases ( $p < .01$ for propionate, the rest $< 0.05$ ). Iso-caproate higher in cases but very small number of samples. Relative distribution of propionate and valerate was higher in controls ( $p < .001$ and $p < .05$ ) and similar trends were seen for i-butyrate i-valerate ( $p = .08$ and $p < .1$ ). Relative distribution of i-caproate and acetate were higher in cases ( $p < .01$ and $p < .001$ ). |
| Stinson et al., Australia, Japan, USA, Norway and South Africa, 2020 cohort studies <sup>54</sup> | 47/62                         | Human milk 1 month after birth, NMR | A, P, B, V, i-V, i-B, formate | Atopy or not: either sensitisation measured by serum IgE or SPT, BA, AD, pet/environmental allergy; FA (either history or diagnosis) | Linear mixed models   | Human milk from atopic women had significantly lower acetate ( $p = .02$ ) and butyrate ( $p = .001$ ), median levels were 57% and 62% lower, respectively. There was difference in countries.  |

Abbreviations: AD, atopic dermatitis/eczema; adjOR, adjusted odds ratio; AR, allergic rhinitis (including hay fever); ARC, allergic rhino-conjunctivitis; BA, asthma; DBPCFC, double blind placebo control food challenge test; FA, food allergy; GC, gas chromatography; GC-MS, gas chromatography-mass spectrometry; HPLC, high-performance liquid chromatography; LC-MS, liquid chromatography mass spectrometry; NMR, nuclear magnetic resonance spectroscopy; OFC, oral food challenge test; OR, odds ratio; RA, respiratory allergy; SPT, skin prick test.

<sup>a</sup>Individual SCFAs are abbreviated as A: acetate, P: propionate, B: butyrate, V: valerate, C: caproate, i-B: iso-butyrate, i-V: iso-valerate, i-C, iso-caproate, BCFAs: branched short chain fatty acids.

TABLE 5 Summary of studies that investigated the association between short chain fatty acids and pre-existing allergic diseases.

| Disease   | Population group                                    | Author, year                                 | Results  |
|---|---|--|--|
| IgE food allergy                                      | Infant  | Berni Canani 2016 <sup>44</sup>              | × butyrate   |
|   |   | Dong 2018 <sup>48</sup>                      | ▼ total SCFA × acetate, propionate, butyrate, iso-butyrate                                     |
|   | Children  | Thompson-Chagoyan 2011 <sup>55</sup>         | △ butyrate, BCFA × acetate, propionate, iso-caproate   |
|   |   | Goldberg 2020 <sup>49</sup>                  | ▼ acetate, propionate, butyrate  |
|   |   | Ho 2021 (saliva) <sup>50</sup>               | ▼ acetate, propionate, butyrate  |
|   |   | De Filippis 2021 <sup>46</sup>               | ▼ propionate, butyrate   |
|   |   | Tian 2022 (serum) <sup>56</sup>              | ▼ acetate, propionate, butyrate  |
|   |   | Zhang 2022 (saliva and faeces) <sup>58</sup> | × acetate, propionate, butyrate  |
| All ages  | Bao 2021 <sup>62</sup>                              | × acetate, propionate, butyrate              |  |
| Atopic dermatitis                                     | Adults <sup>a</sup> (exposure)<br>infants (outcome) | Wang 2022 (breastmilk) <sup>57</sup>         | ▼ acetate, total SCFA × butyrate   |
|   | Adults  | Roesler 2012 <sup>52</sup>                   | ▼ caproate × acetate, butyrate, propionate, valerate, iso-butyrate, iso-valerate               |
|   | Unclear   | Song 2016 <sup>53</sup>                      | ▼ propionate, butyrate × acetate   |
| Non-IgE- cow's milk allergy                           | Infants   | Berni Canani 2018 <sup>43</sup>              | ▼ butyrate   |
|   |   | Diaz 2018 <sup>47</sup>                      | △ BCFA (iso-butyrate, iso-valerate) × acetate, propionate, butyrate                            |
| Allergic rhino-conjunctivitis                         | Adults  | Zhou 2021 (serum) <sup>59</sup>              | ▼ acetate, propionate, butyrate  |
|   |   | Zhou 2021 <sup>60</sup>                      | ▼ acetate, propionate, butyrate × iso-butyrate, iso-valerate                                   |
| Asthma  | Adults  | Jung 2013 (serum) <sup>61</sup>              | ▼ acetate  |
|   |   | Ivashkin 2019 <sup>51</sup>                  | ▼ acetate, propionate, butyrate  |
| Sensitisation (aeroallergen)                          | Children  | De Filippis 2021 <sup>46</sup>               | ▼ propionate, butyrate   |
| Combination of sensitisation and any allergic disease | Infants   | Böttcher 2000 <sup>45</sup>                  | ▼ propionate, butyrate, valerate, iso-butyrate, iso-valerate △ acetate, caproate, iso-caproate |
|   | Adults  | Stinson 2020 (breastmilk) <sup>54</sup>      | ▼ acetate, butyrate × formate, propionate, valerate, iso-butyrate, iso-valerate                |

Note: Levels/concentrations, relative abundance or proportion of individuals with high levels observed in cases were, ▼: decreased, △: increased or ×: not different compared with controls. For the purposes of this review, *p*-value <.05 was considered as a significant association. SCFAs were measured in faecal samples if not stated otherwise.

Abbreviations: BCFA, branched short chain fatty acid; SCFA, short chain fatty acid.

<sup>a</sup>This study measured SCFA levels of breastmilk from mothers of children with and without atopic dermatitis.

Increase, rather than decrease in faecal butyrate and BCFA among cases compared with controls was reported in one Spanish study of infants with IgE-mediated cow's milk allergy (Thompson-Chagoyan et al.).<sup>55</sup>

### 3.10 | SCFAs and pre-existing atopic dermatitis (three papers)

Two studies assessed SCFAs and pre-existing AD in the same individual.<sup>52,53</sup> Song et al. reported decrease in propionate and butyrate among cases compared with healthy controls,<sup>53</sup> while Roesler et al. reported decrease in caproate in cases.<sup>52</sup> A hospital-based case control study (Wang et al.) in Taiwan reported that acetate and total SCFA in the breastmilk from mothers of exclusively

breastfed children was negatively associated with the presence of the children's AD (lowest vs highest quartile, OR 12, 95% CI 2.7–53.3 for acetate and 10.52, 95% CI 2.27–48.76 for total SCFA), and the association with acetate level remained after adjusting for potential confounders including total SCFA (adjOR 0.998, 95% CI 0.9964–0.9996).<sup>57</sup> This study also reported that breastmilk acetate level negatively correlated with objective SCORAD scores of the children's AD.<sup>57</sup>

### 3.11 | SCFAs and pre-existing non-IgE-mediated cow's milk allergy (two papers)

One Italian study reported decrease in butyrate among infants with non-IgE-mediated cow's milk allergy compared with healthy controls

(Berni Canani et al.),<sup>43</sup> and another Spanish study (Díaz et al.) reported increase in BCFAs and tendency of an increase in butyrate among cases.<sup>47</sup>

### 3.12 | SCFAs and pre-existing allergic rhinitis (two papers)

Two separate Chinese hospital-based case control studies, one using faeces,<sup>60</sup> another using serum,<sup>59</sup> reported decrease in all three main SCFAs among adult patients with allergic rhinitis.

### 3.13 | SCFAs and pre-existing asthma (two papers)

Ivashkin et al. assessed the three main SCFAs in the faeces of adult asthma patients and reported decrease in all three compared with healthy controls,<sup>51</sup> and a Korean study using NMR (Jung et al.) reported decrease in serum acetate among cases.<sup>61</sup>

### 3.14 | SCFAs and pre-existing aeroallergen sensitisation (one paper)

Children who were sensitised to aeroallergens were reported to have decreased levels of propionate and butyrate in one Italian hospital-based case control study (De Filippis et al.).<sup>46</sup>

### 3.15 | SCFAs and pre-existing any allergy (two papers)

A paper using data from six birth cohort studies (Stinson et al.) conducted in different countries reported that human milk from mothers who have any allergic disease have decreased level of acetate and butyrate compared to those without.<sup>54</sup> Another Swedish birth cohort study (Böttcher et al.) reported that 1-year-old children who had any allergic disease with sensitisation had decreased level of propionate, butyrate, valerate, iso-butyrate and iso-valerate compared with controls.<sup>45</sup>

## 4 | DISCUSSION

This systematic review summarised the current evidence on the association between SCFAs and allergic diseases. Due to the large variability in methodologies of the included papers, meta-analysis to estimate the effect size of SCFAs for allergic diseases was not possible and we conducted a narrative synthesis of the results. Overall, there was some epidemiological evidence for the association between decrease in the three main SCFAs measured early in life and AD, wheeze/asthma and IgE-mediated food allergy in childhood.

The gut microbiome develops from a relatively simple composition to a more complex adult-like pattern in the first few years of life.<sup>63,64</sup> A shift from the *Bifidobacterium* dominant microbiota to a more diverse microbiota with species of the phyla Bacteroidetes or Firmicutes occurs around the time of solid-food introduction.<sup>63,64</sup> This leads to increase in microbial functionality to break down complex dietary and endogenous carbohydrates, which results in the increase in the production of SCFAs that continues over the first few years of life.<sup>28,65,66</sup> Our results suggest a protective role of SCFAs during this period against childhood allergic diseases and support the hypothesis that disordered functional development of the gut microbiome plays a role in allergic diseases.<sup>29,39</sup>

SCFAs that showed decrease in cases appeared to be different by allergic diseases and by the timing of measurement or disease assessment. This may be due to the difference in the methodologies or study population of the studies included for each disease. However, it may also be due to the difference in the characteristics of these diseases (e.g., organ and onset) and suggest the possibility that there is a timing or disease-specific effect for each SCFA. For studies investigating the association between SCFAs and the development of AD, an association with decreased butyrate was most often reported, as compared to the other SCFAs. In an experimental model of AD-like skin inflammation, it was shown that although supplementation of either acetate, propionate or butyrate led to improvement of clinical outcomes, the effect was the largest for butyrate.<sup>67</sup> Both butyrate and propionate (but not acetate) are known to induce differentiation of naïve T cells into Tregs.<sup>16,68</sup> Butyrate has also been reported to enhance Treg generation by affecting macrophages and dendritic cells.<sup>15</sup> Although our results may suggest a clearer association between AD and butyrate compared with other SCFAs, possibly due to these immunological properties, it is difficult to conclude from the small number of observational studies. The association between the three major SCFAs investigating AD at 6 years old or later was less clear than in studies assessing AD at a younger age. This may suggest that there is a lower protective effect by SCFAs against late-onset AD or persistent AD.

The association between SCFAs and childhood wheeze or asthma appeared to be clearer for acetate when measured in the prenatal period or in early infancy as compared to later time point measurements. This might be partly explained by the differences in the metabolism and production of the SCFAs. Among the three main SCFAs, acetate has the highest concentration in the systemic circulation, since butyrate is mostly absorbed the colonic epithelium and propionate is mainly taken up by the liver.<sup>11</sup> Maternal acetate in systemic circulation can cross the placenta and affect the immune system in the mice foetus, which has also been suggested in human studies.<sup>40,69</sup> Additionally, while the production of butyrate and propionate increase over the first few years of life, the increase in the level of acetate is relatively small.<sup>28,65,66</sup> Thus, the rather unclear protective effect of acetate measured at later time points might be due to the increasing influence of the other SCFAs, such as propionate or butyrate.

Only one out of four studies that investigated the association between the three major SCFAs and development of food allergy

later reported any difference between cases and controls,<sup>31</sup> in which there was only a difference in a small subgroup of children with allergy to specific foods. On the other hand, five out of eight studies on pre-existing childhood IgE-mediated food allergy<sup>46,48-50,56</sup> reported decrease in one or more of the three main SCFAs among cases. This discrepancy might be because studies of pre-existing disease had higher proportions of cases among the total study population due to the study design (case control design) compared with studies of food allergy development (prospective cohort design), and thus had more statistical power to detect a difference. Additionally, only one paper that investigated the development of food allergy diagnosed cases by oral food challenge tests,<sup>41</sup> and otherwise self-reported symptoms or diagnosis was used. Conversely, all studies that investigated children with pre-existing food allergy had their diagnosis clinically confirmed by either sensitisation with a history and/or oral food challenge tests, which may have reduced the possibility of misclassification bias.

None of the studies showed any association between early-life SCFAs and the development of allergic rhinitis. This may suggest that the protective effect of early-life SCFAs are not applicable in the long term for the prevention of allergic rhinitis, which has a later onset than the other allergic diseases. However, two studies assessed the outcome at 6 years, which may have been too early to capture all cases.<sup>34,36</sup> Two case control studies among adult allergic rhinitis patients showed decrease in the three major SCFAs, which suggests that they may have some role in the disease.<sup>59,60</sup>

Compared with acetate, butyrate and propionate, less research is conducted on valerate, caproate and BCFAs, such as iso-butyric acid and iso-valeric acid, which are detected at considerably lower amounts than the major three SCFAs.<sup>10</sup> Five studies investigated valerate and the development AD later in life.<sup>28,30,31,35,42</sup> Decreased level of valerate, but no other SCFA among children who developed AD was reported in two papers,<sup>30,31</sup> and one paper reported a decrease in valerate and butyrate among cases.<sup>35</sup> Some animal studies have demonstrated that valerate upregulates tight junction proteins and keratin,<sup>70,71</sup> which promotes barrier function and plays a role in AD.<sup>72</sup> The association between valerate and the development of food allergy was assessed in three studies,<sup>31,37,41</sup> of which two reported decreased level in cases,<sup>31,37</sup> compared with controls. One of these studies additionally reported decrease in BCFAs among cases,<sup>37</sup> while an increase in BCFA levels among cases was reported in two studies investigating the association with pre-existing IgE-mediated food allergy or non-IgE-mediated cow's milk allergy.<sup>47,55</sup> BCFAs are fermentation products of amino acids and have been shown to correlate negatively with fibre consumption and positively with protein consumption.<sup>10</sup> Since little is known about the molecular mechanisms of BCFAs, it is unclear whether our result suggests a role in the disease, or it is reflecting some difference in the dietary pattern between the comparison groups in these studies.

There are several considerations for the interpretation of these results. Since most SCFAs are rapidly absorbed by the epithelium, faecal concentrations measured at one time point may not accurately

capture the dynamic production of SCFAs and be biased due to the individual characteristics such as intestinal transit or permeability,<sup>73</sup> as well as sample handling methods.<sup>74</sup> Nevertheless, most studies use faecal samples as a proxy for SCFA production in the colon, which is considered a valid approach. Targeting genes in the synthesis pathways, such as butyryl-CoA in butyrate production,<sup>75,76</sup> or quantifying the abundance of known SCFA producers has also been used as an alternative method to investigate SCFA production. However, these methods are also limited since SCFA production is influenced by other factors including the type or abundance of substrates and the characteristics of the gut environment such as pH or oxygen concentration.<sup>76,77</sup> Secondly, the temporal association between SCFAs and disease development was unclear in studies that have assessed SCFAs and the outcome at the same timepoint, and also for studies that assessed SCFAs in infancy and AD, since the onset of disease may have been before SCFAs were measured. Additionally, no clinical trials using SCFAs as intervention have been conducted for allergic diseases up this date. Thus, the decrease in SCFAs among cases in these studies may not be a cause but a consequence of the disease (reverse causation) or that of a risk factor of the disease.

Papers varied in how they reported details of methods such as participant selection, sample analysis method, sensitivity of their method and their results. How participants were selected was often unclear in case control studies and nested case control studies, raising a concern for selection bias. For sample analysis methods, the column or machine used for chromatography-based analysis, or whether standards were used in mass spectroscopy-based methods were not always stated, which may be an issue in terms of the reliability and reproducibility of the results for these studies. Detection limit was only stated in four papers, of which three were from the same study.<sup>31,37,45,54</sup> In general, mass spectrometry in combination with gas chromatography or liquid chromatography are considered as highly sensitive in detecting SCFAs, while nuclear magnetic resonance is less sensitive.<sup>78</sup> However, this can also be affected by sample preparation methods and the type of matrix.<sup>74,79</sup> A small number of studies used serum, breastmilk and saliva, in which SCFA levels were in a considerably lower range compared with faecal samples in line with previous reports.<sup>80,81</sup> Meaningful comparison of SCFA levels between papers were not possible since many papers did not report the observed value or reported different parameters or comparison groups. Standardised reporting of sample analysis method and the results may allow better understanding of the preferred method by each matrix and exploring factors that affect SCFA levels across different populations.

Only 9 out of the total 37 papers (24%) had a sample size of over 100, which may have reduced the statistical power to detect a difference in SCFAs between cases and controls. In fact, some studies showed a tendency of a difference in SCFAs between groups, however, this was not considered as a significant association for the purpose of this review. The relatively small sample size has also limited the possibility of accounting for potential confounders for

the association between SCFAs and allergic disease in these studies, suggesting the possibility of residual confounding. Only five of the 17 studies in the SCFAs and development of allergy category,<sup>28,30,33,35,39</sup> and one study in the pre-existing allergic diseases category,<sup>57</sup> accounted for factors besides sex and age in their design or analysis. Finally, the possible influence of publication bias, where studies with statistically significant positive results were more likely to be published and thus included in this review, needs to be taken into consideration.

The association between dietary factors and SCFA levels were evaluated in a few studies. Breastfeeding was negatively correlated with propionate,<sup>36,42</sup> butyrate<sup>36,42</sup> or BCFAs.<sup>42</sup> Higher butyrate level at 1 year was associated with early introduction or longer duration of consumption of yogurt, fish,<sup>36,38</sup> or vegetables and fruit.<sup>36</sup> Dietary fibre intake at 1 year was negatively associated with faecal iso-butyric and iso-valeric acid at 3 years in a Swedish rural cohort.<sup>30</sup> One study showed that fibre intake of the mother was positively correlated with faecal SCFA levels, but not with the offspring outcome.<sup>34</sup> Several studies in animal models have shown results supporting the potential link between dietary fibre, which is the major substrate for SCFA production, SCFAs and allergic diseases. High fibre diet increased the production of SCFAs in mice and was shown to be protective against food allergy,<sup>82</sup> allergic inflammation in the lung<sup>21,40</sup> and AD-like skin inflammation, although<sup>67</sup> this link is less clearly described in studies among humans.<sup>83-85</sup> A recent systematic review has reported that there is some evidence on the protective effect of higher intake of dietary fibre against asthma or respiratory symptoms in humans, while the association was unclear for atopic dermatitis, allergic rhinitis and food allergy, with only small number of studies.<sup>86</sup> An effective and feasible dietary intervention using dietary fibre that can increase SCFA levels as well as affect the immune system is an important topic for future research.

In conclusion, this systematic review showed that there was some evidence for the protective effect of early life SCFA against childhood allergic diseases. The evidence was clearer for the role of early life SCFAs in the development of atopic dermatitis or wheeze/asthma later in childhood, and for pre-existing IgE-mediated food allergy in childhood. Further research that would determine the timing specific effect of each SCFA and uncover the mechanisms by which SCFA levels in the human body can be modified, will be useful to identify how SCFAs can be used in treatment or in prevention against allergic diseases.

#### AUTHOR CONTRIBUTIONS

MS, RF, LO, CV, RL and CR were involved in the conception of the study. MS, NS, JA, KH, RF and CR performed the article search and screening, MS and NS extracted and summarised the data. MS wrote the manuscript and all authors provided critical feedback.

#### ACKNOWLEDGEMENTS

We thank Martina Gosteli for her support in constructing the search terms. Open access funding provided by Universitat Zurich.

#### FUNDING INFORMATION

No funding was obtained for this study.

#### CONFLICT OF INTEREST STATEMENT

All authors have nothing to declare within the scope of this work.

#### DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

#### ORCID

Mari Sasaki  <https://orcid.org/0000-0003-1590-3838>

Noor H. A. Suaini  <https://orcid.org/0000-0003-1161-8845>

Liam O'Mahony  <https://orcid.org/0000-0003-4705-3583>

Carina Venter  <https://orcid.org/0000-0002-7473-5355>

Caroline Roduit  <https://orcid.org/0000-0002-5988-0570>

#### REFERENCES

- Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. *Cell Res.* 2020;30(6):492-506.
- Huang YJ, Marsland BJ, Bunyavanich S, et al. The microbiome in allergic disease: current understanding and future opportunities-2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European academy of allergy and clinical immunology. *J Allergy Clin Immunol.* 2017;139(4):1099-1110.
- Zimmermann P, Messina N, Mohn WW, Finlay BB, Curtis N. Association between the intestinal microbiota and allergic sensitization, eczema, and asthma: a systematic review. *J Allergy Clin Immunol.* 2019;143(2):467-485.
- Watanabe S, Narisawa Y, Arase S, et al. Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. *J Allergy Clin Immunol.* 2003;111(3):587-591.
- Hua X, Goedert JJ, Pu A, Yu G, Shi J. Allergy associations with the adult fecal microbiota: analysis of the American gut project. *EBioMedicine.* 2016;3:172-179.
- Hevia A, Milani C, López P, et al. Allergic patients with long-term asthma display low levels of Bifidobacterium adolescentis. *PLoS One.* 2016;11(2):e0147809.
- Watts AM, West NP, Zhang P, Smith PK, Cripps AW, Cox AJ. The gut microbiome of adults with allergic rhinitis is characterised by reduced diversity and an altered abundance of key microbial taxa compared to controls. *Int Arch Allergy Immunol.* 2021;182(2):94-105.
- Yang W, Cong Y. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases. *Cell Mol Immunol.* 2021;18(4):866-877.
- Postler TS, Ghosh S. Understanding the Holobiont: how microbial metabolites affect human health and shape the immune system. *Cell Metab.* 2017;26(1):110-130.
- Rios-Covian D, González S, Nogacka AM, et al. An overview on fecal branched short-chain fatty acids along human life and as related with body mass index: associated dietary and anthropometric factors. *Front Microbiol.* 2020;11:973.
- Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. *Proc Nutr Soc.* 2003;62(1):67-72.
- Parada Venegas D, De la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. *Front Immunol.* 2019;10:277.
- Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: an overlooked therapy for IBD? *EBioMedicine.* 2021;66:103293.

14. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. *Adv Immunol.* 2014;121:91-119.
15. Singh N, Gurav A, Sivaprakasam S, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity.* 2014; 40(1):128-139.
16. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature.* 2013;504(7480):451-455.
17. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature.* 2013;504(7480):446-450.
18. Gill PA, van Zelm MC, Muir JG, Gibson PR. Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. *Aliment Pharmacol Ther.* 2018; 48(1):15-34.
19. Xiao X, Hu X, Yao J, et al. The role of short-chain fatty acids in inflammatory skin diseases. *Front Microbiol.* 2023;13:1083432.
20. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. *Nat Rev Gastroenterol Hepatol.* 2019;16(8):461-478.
21. Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. *Nat Med.* 2014;20(2):159-166.
22. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ (Clinical Research Ed).* 2021;372:n71.
23. Viant MR, Kurland IJ, Jones MR, Dunn WB. How close are we to complete annotation of metabolomes? *Curr Opin Chem Biol.* 2017;36:64-69.
24. Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical analysis chemical analysis working group (CAWG) metabolomics standards initiative (MSI). *Metabolomics.* 2007;3(3):211-221.
25. Hootman JM, Driban JB, Sitler MR, Harris KP, Cattano NM. Reliability and validity of three quality rating instruments for systematic reviews of observational studies. *Res Synth Methods.* 2011;2(2):110-118.
26. Arrieta MC, Arévalo A, Stiemsma L, et al. Associations between infant fungal and bacterial dysbiosis and childhood atopic wheeze in a nonindustrialized setting. *J Allergy Clin Immunol.* 2018;142(2):424-434.e10.
27. Arrieta MC, Stiemsma LT, Dimitriu PA, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. *Sci Transl Med.* 2015;7(307):307ra152.
28. Cheng HY, Chan JCY, Yap GC, et al. Evaluation of stool short chain fatty acids profiles in the first year of life with childhood atopy-related outcomes. *Front Allergy.* 2022;3:873168.
29. Depner M, Taft DH, Kirjavainen PV, et al. Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma. *Nat Med.* 2020;26(11):1766-1775.
30. Gio-Batta M, Sjöberg F, Jonsson K, et al. Fecal short chain fatty acids in children living on farms and a link between valeric acid and protection from eczema. *Sci Rep.* 2020;10(1):22449.
31. Gio-Batta M, Spetz K, Barman M, et al. Low concentration of fecal Valeric acid at 1 year of age is linked with eczema and food allergy at 13 years of age: findings from a Swedish birth cohort. *Int Arch Allergy Immunol.* 2022;183(4):398-408.
32. Kim HK, Rutten NBMM, Besseling-van der Vaart I, et al. Probiotic supplementation influences faecal short chain fatty acids in infants at high risk for eczema. *Beneficial Microbes.* 2015;6(6):783-790.
33. Lee MJ, Park YM, Kim B, et al. Disordered development of gut microbiome interferes with the establishment of the gut ecosystem during early childhood with atopic dermatitis. *Gut Microbes.* 2022;14(1):2068366.
34. Lee-Sarwar KA, Kelly RS, Lasky-Su J, et al. Fecal short-chain fatty acids in pregnancy and offspring asthma and allergic outcomes. *J Allergy Clin Immunol Pract.* 2020;8(3):1100-1102.e13.
35. Park YM, Lee SY, Kang MJ, et al. Imbalance of gut streptococcus, clostridium, and Akkermansia determines the natural course of atopic dermatitis in infant. *Allergy Asthma Immunol Res.* 2020;12(2):322-337.
36. Roduit C, Frei R, Ferstl R, et al. High levels of butyrate and propionate in early life are associated with protection against atopy. *Allergy.* 2019;74(4):799-809.
37. Sandin A, Bråbäck L, Norin E, Björkstén B. Faecal short chain fatty acid pattern and allergy in early childhood. *Acta Paediatr.* 2009;98(5):823-827.
38. Sasaki M, Schwab C, Ramirez Garcia A, et al. The abundance of Ruminococcus bromii is associated with faecal butyrate levels and atopic dermatitis in infancy. *Allergy.* 2022;77:3629-3640.
39. Ta LDH, Chan JCY, Yap GC, et al. A compromised developmental trajectory of the infant gut microbiome and metabolome in atopic eczema. *Gut Microbes.* 2020;12(1):1-22.
40. Thorburn AN, McKenzie CI, Shen S, et al. Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. *Nat Commun.* 2015;6:7320.
41. Vuillermin PJ, O'Hely M, Collier F, et al. Maternal carriage of Prevotella during pregnancy associates with protection against food allergy in the offspring. *Nat Commun.* 2020;11(1):1452.
42. Wopereis H, Sim K, Shaw A, Warner JO, Knol J, Kroll JS. Intestinal microbiota in infants at high risk for allergy: effects of prebiotics and role in eczema development. *J Allergy Clin Immunol.* 2018;141(4):1334-1342.e5.
43. Berni Canani R, De Filippis F, Nocerino R, et al. Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy. *Sci Rep.* 2018;8(1):12500.
44. Berni Canani R, Sangwan N, Stefka AT, et al. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants. *ISME J.* 2016;10(3):742-750.
45. Böttcher MF, Nordin EK, Sandin A, Midtvedt T, Björkstén B. Microflora-associated characteristics in faeces from allergic and nonallergic infants. *Clin Exp Allergy.* 2000;30(11):1590-1596.
46. De Filippis F, Paparo L, Nocerino R, et al. Specific gut microbiome signatures and the associated pro-inflammatory functions are linked to pediatric allergy and acquisition of immune tolerance. *Nat Commun.* 2021;12(1):5958.
47. Díaz M, Guadamuro L, Espinosa-Martos I, et al. Microbiota and derived parameters in fecal samples of infants with non-IgE Cow's Milk protein allergy under a restricted diet. *Nutrients.* 2018; 10(10):1481.
48. Dong Y, Fei P, Han Y, Guo L. Characterization of fecal microbiota, short-chain fatty acids and lactic acid concentrations in 5 - 8-year-old children with cow Milk protein allergy. *Innov J Pediatr.* 2018;28(4):e64638.
49. Goldberg MR, Mor H, Magid Neriya D, et al. Microbial signature in IgE-mediated food allergies. *Genome Med.* 2020;12(1):92.
50. Ho HE, Chun Y, Jeong S, Jumreornvong O, Sicherer SH, Bunyavanich S. Multidimensional study of the oral microbiome, metabolite, and immunologic environment in peanut allergy. *J Allergy Clin Immunol.* 2021;148(2):627-632.e3.
51. Ivashkin V, Zolnikova O, Potskherashvili N, et al. Metabolic activity of intestinal microflora in patients with bronchial asthma. *Clin Pract.* 2019;9(1):1126.
52. Roessler A, Forssten SD, Gleim M, Ouwehand AC, Jahreis G. The effect of probiotics on faecal microbiota and genotoxic activity of faecal water in patients with atopic dermatitis: a randomized, placebo-controlled study. *Clin Nutr.* 2012;31(1):22-29.

53. Song H, Yoo Y, Hwang J, Na YC, Kim HS. Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. *J Allergy Clin Immunol*. 2016;137(3):852-860.
54. Stinson LF, Gay MCL, Koleva PT, et al. Human Milk from atopic mothers has lower levels of short chain fatty acids. *Front Immunol*. 2020;11:1427.
55. Thompson-Chagoyan OC, Fallani M, Maldonado J, et al. Faecal microbiota and short-chain fatty acid levels in faeces from infants with cow's milk protein allergy. *Int Arch Allergy Immunol*. 2011;156(3):325-332.
56. Tian GX, Peng KP, Yu Y, et al. Propionic acid regulates immune tolerant properties in B cells. *J Cell Mol Med*. 2022;26(10):2766-2776.
57. Wang LC, Huang YM, Lu C, et al. Lower caprylate and acetate levels in the breast milk is associated with atopic dermatitis in infancy. *Pediatr Allergy Immunol*. 2022;33(2):e13744.
58. Zhang L, Chun Y, Ho HE, et al. Multiscale study of the oral and gut environments in children with high- and low-threshold peanut allergy. *J Allergy Clin Immunol*. 2022;150(3):714-720.e2.
59. Zhou CJ, Xie BL, Han HY, et al. Short-chain fatty acids promote immunotherapy by modulating immune regulatory property in B cells. *J Immunol Res*. 2021;2021:2684361.
60. Zhou MS, Zhang B, Gao ZL, et al. Altered diversity and composition of gut microbiota in patients with allergic rhinitis. *Microb Pathog*. 2021;161(Pt A):105272.
61. Jung J, Kim SH, Lee HS, et al. Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. *Clin Exp Allergy*. 2013;43(4):425-433.
62. Bao R, Hesser LA, He Z, Zhou X, Nadeau KC, Nagler CR. Fecal microbiome and metabolome differ in healthy and food-allergic twins. *J Clin Invest*. 2021;131(2):e141935.
63. Stewart CJ, Ajami NJ, O'Brien JL, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. *Nature*. 2018;562(7728):583-588.
64. Bäckhed F, Roswall J, Peng Y, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host Microbe*. 2015;17(5):690-703.
65. Łoniewska B, Fraszczyk-Tousty M, Tousty P, Skonieczna-Żydecka K, Maciejewska-Markiewicz D, Łoniewski I. Analysis of fecal short-chain fatty acids (SCFAs) in healthy children during the first two years of life: an observational prospective cohort study. *Nutrients*. 2023;15(2):367.
66. Appert O, Garcia AR, Frei R, et al. Initial butyrate producers during infant gut microbiota development are endospore formers. *Environ Microbiol*. 2020;22(9):3909-3921.
67. Trompette A, Pernot J, Perdijk O, et al. Gut-derived short-chain fatty acids modulate skin barrier integrity by promoting keratinocyte metabolism and differentiation. *Mucosal Immunol*. 2022;15(5):908-926.
68. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science*. 2013;341(6145):569-573.
69. Hu M, Eviston D, Hsu P, et al. Decreased maternal serum acetate and impaired fetal thymic and regulatory T cell development in pre-eclampsia. *Nat Commun*. 2019;10(1):3031.
70. Li Y, Dong J, Xiao H, et al. Gut commensal derived-valeric acid protects against radiation injuries. *Gut Microbes*. 2020;11(4):789-806.
71. Nguyen TD, Hällenius FF, Lin X, Nyman M, Prykhodko O. Monobutyrin and Monovalerin affect brain short-chain fatty acid profiles and tight-junction protein expression in ApoE-knockout rats fed high-fat diets. *Nutrients [Internet]*. 2020;12(4):1202.
72. Beck LA, Cork MJ, Amagai M, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. *JID Innov*. 2022;2(5):100131.
73. Lewis SJ, Heaton KW. Increasing butyrate concentration in the distal colon by accelerating intestinal transit. *Gut*. 1997;41(2):245-251.
74. Primec M, Mičetić-Turk D, Langerholc T. Analysis of short-chain fatty acids in human feces: a scoping review. *Anal Biochem*. 2017;526:9-21.
75. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon. *FEMS Microbiol Lett*. 2002;217(2):133-139.
76. Louis P, Young P, Holtrop G, Flint HJ. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. *Environ Microbiol*. 2010;12(2):304-314.
77. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. *FEMS Microbiol Lett*. 2009;294(1):1-8.
78. Cai J, Zhang J, Tian Y, et al. Orthogonal comparison of GC-MS and (1)H NMR spectroscopy for short chain fatty acid quantitation. *Anal Chem*. 2017;89(15):7900-7906.
79. Chalova P, Tazky A, Skultety L, et al. Determination of short-chain fatty acids as putative biomarkers of cancer diseases by modern analytical strategies and tools: a review. *Front Oncol*. 2023;13:1110235.
80. Priyadarshini M, Thomas A, Reisetter AC, et al. Maternal short-chain fatty acids are associated with metabolic parameters in mothers and newborns. *Transl Res*. 2014;164(2):153-157.
81. Nogal A, Asnicar F, Vijay A, et al. Genetic and gut microbiome determinants of SCFA circulating and fecal levels, postprandial responses and links to chronic and acute inflammation. *Gut Microbes*. 2023;15(1):2240050.
82. Tan J, McKenzie C, Vuillermin PJ, et al. Dietary fiber and bacterial SCFA enhance Oral tolerance and protect against food allergy through diverse cellular pathways. *Cell Rep*. 2016;15(12):2809-2824.
83. Gill PA, Muir JG, Gibson PR, van Zelm MC. A randomized dietary intervention to increase colonic and peripheral blood short-chain fatty acids modulates the blood B- and T-cell compartments in healthy humans. *Am J Clin Nutr*. 2022;116(5):1354-1367.
84. Vanegas SM, Meydani M, Barnett JB, et al. Substituting whole grains for refined grains in a 6-wk randomized trial has a modest effect on gut microbiota and immune and inflammatory markers of healthy adults. *Am J Clin Nutr*. 2017;105(3):635-650.
85. West NP, Christophersen CT, Pyne DB, et al. Butyrylated starch increases colonic butyrate concentration but has limited effects on immunity in healthy physically active individuals. *Exerc Immunol Rev*. 2013;19:102-119.
86. Venter C, Meyer RW, Greenhawt M, et al. Role of dietary fiber in promoting immune health-an EAACI position paper. *Allergy*. 2022;77(11):3185-3198.

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Sasaki M, Suaini NHA, Afghani J, et al. Systematic review of the association between short chain fatty acids and allergic diseases. *Allergy*. 2024;00:1-23. doi:[10.1111/all.16065](https://doi.org/10.1111/all.16065)